Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.
The company's shares are trading at their lowest since August 2023. Source: xStation
AMD āļāđāļēāļāļ Nvidia āđāļāđāļāļēāļŦāļĨāļĩāđāļāđ āļāđāļ§āļĒāļāļĩāļĨāļāļīāļ 10,000 āļāļąāļ§
āļŦāļļāđāļ SAP āļāļĢāļąāļāļāļąāļ§āļĨāļāļĨāļ 4% āđāļĄāđāđāļāđāļĢāļąāļāļāļģāđāļāļ°āļāļģāđāļāļīāļāļāļ§āļāļāļēāļ Bernstein
â° āļŦāļļāđāļ GRAB āđāļāļāļāļĢāļĩ
HALO Trade āļāļ·āļāļāļ°āđāļĢ? âSafe Havenâ āļĒāļļāļāđāļĄāđāđāļāđāļāļāļ
